Filing Flows › Health Care › Cardio Diagnostics Holdings (CDIO)
Cardio Diagnostics Holdings (CDIO) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 6, 2026 · Cardio Diagnostics Holdings (CDIO) Q3 2026 earnings results →
Q3 2026 Revenue up 26% year over year to $4K
Cardio Diagnostics Holdings made $4K in Q3 2026 (+26% Y/Y). Operating margin n/m, net loss $1.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $4K in Q3 2026, up 26% year over year and down 33% from the previous quarter.
Operating costs exceeded revenue by $1.7M, an operating margin of -48193.8%. Total costs grew 1% against revenue growth of 26%. The quarter ended with a net loss of $1.7M, wider than the previous quarter's $1.5M loss.
Operating cash flow was −$1.5M. Non-cash charges added back $6K of depreciation and amortization and $24K of share-based compensation. Working capital and other items added $186K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 6, 2026 | $4K | +26% | n/m | −$1.7M | −$1.5M |
| Q2 2026 | 10-Q | Aug 7, 2026 | $5K | -28% | n/m | −$1.5M | −$1.3M |
| Q1 2026 | 10-Q | May 15, 2026 | $3K | +185% | n/m | −$1.8M | −$1.6M |
| Q4 2025 | 10-K | Mar 13, 2026 | $4K | -21% | n/m | −$1.5M | −$1.4M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $3K | -57% | n/m | −$1.7M | −$1.4M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $7K | -5% | n/m | −$1.7M | −$1.6M |
| Q1 2025 | 10-Q | May 15, 2025 | $1K | -94% | n/m | −$1.6M | −$1.4M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Cardio Diagnostics Holdings
The following (a) consolidated balance sheet as of December 31, 2025, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim financial statements of the Company as of June 30, 2026 and for the six and three months ended June 30, 2026 and 2025 have been prepared in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six and three months ended June 30, 2026 are not necessarily indicative of results that may be expected for the year ending December 31, 2026 or any future periods.
In its own words, from its 10-Q, filed Aug 7, 2026.
Cardio Diagnostics Holdings against its In Vitro & In Vivo Diagnostic Substances peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +26% against the peers' median +6%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CDIO Cardio Diagnostics Holdings | Q3 2026 | $4K | +26% | n/m |
| IDXX Idexx Laboratories | Q3 2026 | $1.2B | +10% | 33.1% |
| QDEL QuidelOrtho | Q3 2026 | $619M | -12% | -1.2% |
| LNTH Lantheus Holdings | Q3 2026 | $390M | +2% | 8.3% |
| NEOG Neogen | Q1 FY27 | $223M | +6% | -0.8% |
| MYGN Myriad Genetics | Q3 2026 | $203M | -2% | -19.7% |
| TKNO Alpha Teknova | Q3 2026 | $12.7M | +22% | -25.2% |
| ICCC Immucell | Q2 2026 | $7.2M | +12% | 26.9% |
| NTLA Intellia Therapeutics | Q3 2026 | $7.2M | -48% | n/m |
Source: Cardio Diagnostics Holdings 10-Q on SEC EDGAR · CIK 1870144 · In Vitro & In Vivo Diagnostic Substances
Guidance and outlook
13F: who owns CDIO and who is buying
More on CDIO
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results